Europe High Content Screening Market Introduction and Overview
According to SPER Market Research, the Europe High Content Screening Market is estimated to reach USD 1979.69 million by 2033 with a CAGR of 7.01%.
HCS is connected with high-throughput screening (HTS), in which a large number of mixtures are tried in lined up for their movement in at least one organic examination, however includes tests of additional complex cell aggregates as results. In high-satisfied screening, cells are first brooded with the substance and after a few times, the designs and sub-atomic parts of the cells are dissected. The most well-known examination includes naming proteins with fluorescent labels, lastly, changes in cell aggregate are estimated utilizing computerized picture investigation. Using fluorescent labels with various retention and discharge maxima, estimating a few different cell parts in parallel is conceivable. Besides, the imaging can identify changes at a subcellular level (e.g., cytoplasm versus core versus different organelles). Thus, an enormous number of information focuses can be gathered per cell. However fluorescent naming, different mark-free tests have been utilized in high-satisfied screening.
- January 2023; Axion BioSystems declared the expansion of the Omni Star 12 to the Omni live-cell imaging item family. The new stage, in which elements coordinated advanced mechanics and different plans viable with any standard hatchery, offers upgraded adaptability and proficiency to researchers and medication designers leading live-cell imaging tests. This headway in the imaging strategy would assist with tranquilizing disclosure and be effective by having live cell imaging tests.
- December 2019; Olympus reported the U.S. send-off of the scanR HCS station, a cell imaging arrangement that uses Man-made reasoning (simulated intelligence) to empower cutting-edge natural examination. It joins the measured quality and adaptability of a magnifying lens-based arrangement with the robotization, speed, throughput, and reproducibility of an HCS station.
Market Opportunities and Challenges
Opportunities- Artificial intelligence strategies, such as AI and profound learning, can dissect enormous volumes of information produced in drug revelation and advancement processes. By handling different datasets, including HTS information, substance and organic data sets, and clinical preliminary information, man-made intelligence calculations can distinguish, connections, and patterns that may not be promptly obvious to human scientists. This can assist with speeding up the distinguishing proof of potential medication applicants and advance the medication revelation process. Information science and artificial intelligence are turning out to be progressively significant in drug revelation and advancement. As well as creating new therapeutics, simulated intelligence speeds up crafted by existing medication disclosure and clinical groups, assisting them with pursuing informed and profoundly exact exploration choices.
Challenges- HCS requires mastery in dealing with complex imaging frameworks, information examination programming, and measure improvement. Unpractised administrators might battle to upgrade conventions, prompting poor execution and compromised results. Gifted experts are essential for getting solid and top-notch information from HCS measures. Consequently, the absence of talented and ensured experts to work HCS is supposed to represent a test to showcase development. Shortage of Proficient and gifted administrators of HCS instruments CS instruments like stream cytometers and multimode perusers have somewhat complex advancements. Specialists with a decent information on cell-based measures and taking care of programming and instruments are expected for their ideal usage. Nonetheless, there is a critical lack of gifted faculty in this market. An overview led by the Relationship of the English Drug Industry (ABPI) in the U.K. uncovered an absence of gifted work force in drug organizations. Around 93 workers from 59 drug organizations took part in the study.
Market Competitive Landscape
The Europe High Content Screening Market is a highly competitive arena due to the presence of multiple global and regional companies in the competitive environment. Leading companies in the industry are Axxam S.p.A., BD, Carl Zeiss AG, Corning Incorporated, Merck KGaA, Molecular Devices, LLC. (Subsidiary of Danaher Corporation), PerkinElmer Inc., Sartorius AG, Thermo Fisher Scientific Inc., and Zifo RnD Solutions.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Product Type, By Technology, By Application, By Distribution Channel
|
| Regions covered | Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Denmark, Netherlands, Switzerland, Sweden, Poland, Norway, Finland, and Rest of Europe
|
| Companies Covered | Axxam S.p.A., BD, Carl Zeiss AG, Corning Incorporated, Merck KGaA, Molecular Devices, LLC. (Subsidiary of Danaher Corporation), PerkinElmer Inc., Sartorius AG, Thermo Fisher Scientific Inc., and Zifo RnD Solutions.
|
COVID-19 Impact on Europe High Content Screening Market
The episode of Coronavirus has accelerated the adoption of remote work and cloud-based data analysis solutions. Researchers adapted by using virtual platforms for collaboration and data sharing, which increased the efficiency of HCS data management and analysis. Lockdowns and restrictions disrupted the supply chains for HCS equipment and reagents, leading to delays in research timelines and increased costs. This disruption highlighted the need for more resilient supply chains and local production capabilities. There was an increase in collaborations between research institutions, biotech companies, and pharmaceutical firms as they worked together to address the pandemic. These collaborations often utilized HCS technologies to expedite the development of COVID-19 treatments.
Key Target Audience:
- Pharmaceutical Companies
- Biotechnology Firms
- Academic and Research Institutions
- Contract Research Organizations (CROs)
- Diagnostic Companies
- Government and Public Health Agencies
Our in-depth analysis of the Europe High Content Screening Market includes the following segments:
|
By Product Type:
|
Instruments
Consumables
Software
Services
Accessories
|
|
By Application:
|
Primary and Secondary Screening
Target Identification & Validation
Toxicity Studies
Compound Profiling
Others
|
|
By Technology:
|
Microscopy
Flow Cytometry
Extracellular Matrix Based Scaffold
Western Blotting
ELISA
Immunohistochemistry
Others
|
|
By Distribution Channel:
|
Direct Tenders
Retail Sales
|
Key Topics Covered in the Report:
- Europe High Content Screening Market Size (FY’2024-FY’2033)
- Overview of Europe High Content Screening Market
- Segmentation of Europe High Content Screening Market by Product Type (Instruments, Consumables, Software, Services, Accessories)
- Segmentation of Europe High Content Screening Market by Application (Primary and Secondary Screening, Target Identification & Validation, Toxicity Studies, Compound Profiling, Others)
- Segmentation of Europe High Content Screening Market by Technology (G Microscopy, Flow Cytometry, Extracellular Matrix Based Scaffold, Western Blotting, ELISA, Immunohistochemistry, Others)
- Segmentation of Europe High Content Screening Market by Distribution Channel (Direct Tenders, Retail Sales)
- Statistical Snap of Europe High Content Screening Market
- Expansion Analysis of Europe High Content Screening Market
- Problems and Obstacles in Europe High Content Screening Market
- Competitive Landscape in the Europe High Content Screening Market
- Impact of COVID-19 and Demonetization on Europe High Content Screening Market
- Details on Current Investment in Europe High Content Screening Market
- Competitive Analysis of Europe High Content Screening Market
- Prominent Players in the Europe High Content Screening Market
- SWOT Analysis of Europe High Content Screening Market
- Europe High Content Screening Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity, and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Europe High Content Screening Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Europe High Content Screening Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe High Content Screening Market
7. Europe High Content Screening Market, By Product Type (USD Million) 2020-2033
7.1. Europe High Content Screening Market Size, Share and Forecast, By Product Type, 2020-2026
7.2. Europe High Content Screening Market Size, Share and Forecast, By Product Type, 2027-2033
7.3. Instruments
7.4. Consumables
7.5. Software
7.6. Services
7.7. Accessories
8. Europe High Content Screening Market, By Application (USD Million) 2020-2033
8.1. Europe High Content Screening Market Size, Share and Forecast, By Application, 2020-2026
8.2. Europe High Content Screening Market Size, Share and Forecast, By Application, 2027-2033
8.3. Primary and Secondary Screening
8.4. Target Identification & Validation
8.5. Toxicity Studies
8.6. Compound Profiling
8.7. Others
9. Europe High Content Screening Market, By Technology (USD Million) 2020-2033
9.1. Europe High Content Screening Market Size, Share and Forecast, By Technology, 2020-2026
9.2. Europe High Content Screening Market Size, Share and Forecast, By Technology, 2027-2033
9.3. Microscopy
9.4. Flow Cytometry
9.5. Extracellular Matrix Based Scaffold
9.6. Western Blotting
9.7. ELISA
9.8. Immunohistochemistry
9.9. Others
10. Europe High Content Screening Market, By Distribution Channel (USD Million) 2020-2033
10.1. Europe High Content Screening Market Size, Share and Forecast, Distribution Channel, 2020-2026
10.2. Europe High Content Screening Market Size, Share and Forecast, By Distribution Channel, 2027-2033
10.3. Direct Tenders
10.4. Retail Sales
11. Europe High Content Screening Market Forecast, 2020-2033 (USD Million)
11.1. Europe High Content Screening Market Size and Market Share
12. Europe High Content Screening Market, By Region, 2020-2033 (USD Million)
12.1. Europe High Content Screening Market Size and Market Share By Region (2020-2026)
12.2. Europe High Content Screening Market Size and Market Share By Region (2027-2033)
12.3. Germany
12.4. France
12.5. U.K.
12.6. Italy
12.7. Spain
12.8. Russia
12.9. Turkey
12.10. Belgium
12.11. Denmark
12.12. Netherlands
12.13. Switzerland
12.14. Sweden
12.15. Poland
12.16. Norway
12.17. Finland
12.18. Rest of Europe
13. Company Profile
13.1. Axxam S.p.A.
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. BD
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Carl Zeiss AG
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Corning Incorporated
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Merck KGaA
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. Molecular Devices LLC. (Subsidiary of Danaher Corporation)
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. PerkinElmer Inc.
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Sartorius AG
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Thermo Fisher Scientific Inc.
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Zifo RnD Solutions
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
